Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel polymeric micelle formulation - Samyang

Next Previous
Drug Profile

Paclitaxel polymeric micelle formulation - Samyang

Alternative Names: Cremophor EL-free polymeric micelle of paclitaxel; Cynviloq; Genexol-PM; Genexsol; IG-001; NANT-008; Nant-paclitaxel; paclitaxel loaded polymeric micelle - Samyang

Latest Information Update: 10 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Boryung Pharmaceutical; NantPharma; Samyang Biopharmaceuticals Corporation; Samyang Group; Sorrento Therapeutics
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase II Bladder cancer; Pancreatic cancer
  • Phase I/II Gastric cancer
  • No development reported Gynaecological cancer

Most Recent Events

  • 06 Dec 2023 NantPharma withdraws a phase Ib/II trial in Pancreatic cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unrespectable) in USA (IV) prior to enrolment (NCT03127124)
  • 02 Dec 2023 Samyang Biopharm and Boryung Pharmaceutical completes a phase-I/II trial in Gastric cancer (Late-stage disease) in South Korea (Intraperitoneal) (NCT03618758)
  • 02 Jun 2023 Adverse events and efficacy data from a phase II trial in Pancreatic cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top